Method of using an electrochemical test sensor

Abstract
A method of distinguishing a control solution from a sample in an electrochemical test sensor is performed. The method includes adding a control marker to the control solution. The control solution includes the control marker and analyte. The test sensor includes working and counter electrodes, and a reagent. A potential is applied to the test sensor to oxidize the control marker and the analyte. The resulting electrical current is measured. A potential is applied to the test sensor lower than the other potential in which the potential is sufficient to oxidize the analyte and not the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents. To increase the measured current, a salt may be added to the control solution in an amount sufficient to increase the electrical current by at least 5% as compared to a control solution in the absence of a salt.
Description
FIELD OF THE INVENTION

The present invention generally relates to a method of using an electrochemical test sensor. More specifically, the present invention generally relates to using control markers for auto-detection of the control solution in electrochemical test sensors.


BACKGROUND OF THE INVENTION

The quantitative determination of analytes in body fluids is of great importance in the diagnoses and maintenance of certain physical conditions. For example, lactate, cholesterol and bilirubin should be monitored in certain individuals. In particular, it is important that individuals with diabetes frequently check the glucose level in their body fluids to regulate the glucose intake in their diets. The results of such tests can be used to determine what, if any, insulin or other medication needs to be administered. In one type of blood-glucose testing system, test sensors are used to test a sample of blood.


The test sensor is adapted to receive fluid (e.g., blood) from a user. The test sensor typically includes a base and a lid that is attached to the base. One type of test sensor is an electrochemical test sensor that is adapted to test for an analyte (e.g., glucose). Electrochemical test sensors typically include at least two electrodes to analyze the analyte concentration of the sample. These electrodes of the test sensor are in electrical communication with a meter or instrument that is configured to test for the analyte concentration.


A potential is applied to the electrodes in contact with a biological sample and reagents. The resulting current is measured while the analyte is reacting with the reagents, and then correlated with the amount of an analyte in the sample. Such instruments are referred to as amperometric, in contrast with coulometric instruments that measure the total charge in coulombs produced from reaction of the sample by integrating the current over the entire measurement time. The amperometric instruments are advantageous in that they can use smaller samples and perform quicker tests. Specifically, amperometric instruments do not need to wait for the entire volume of the analyte to be reacted, but rather may take measurements of the analyte by sampling the reaction rate at a predetermined time.


To obtain more accurate measurements, control solutions containing known amounts of glucose are used to verify that the instrument is operating properly. Control solutions have been used that contain blood serum. Some control solutions have been used that replace serum-based control solutions with solutions free of serum, since serum-free solutions are more consistent and stable than those containing serum. Control solutions may contain multiple fixed levels of an analyte concentration (e.g., two or three fixed glucose concentrations) that are formulated to mimic blood serum in terms of fluidity.


Control solutions are used to check the functionality of the analyte monitoring device or meter. Control solutions need to be identified and separated from the readings of real whole blood samples. Specifically, there is a need to automatically detect the control solution by the meter for several reasons. First, the temperature coefficients of the control solution and whole blood may be different. Thus, it is desirable to compensate the temperature effect on glucose readings with separate temperature coefficients. Second, by automatically detecting the control solution and not recording its reading into the memory of real blood-glucose readings assists to provide a more accurate average of blood-glucose readings. Without eliminating the control-solution readings, control solutions will be included in the history of the glucose measurements. Having incorrect historical readings may lead to an incorrect interpretation of a patient's diabetic condition. Additionally, if a control solution is substituted for a whole blood sample, it may be erroneously considered by a physician as indicating a need to change treatment. Third, automatically detecting the control solution and not recording its reading into the memory of blood-glucose readings may minimize the chance of faking the blood-glucose readings by control solution.


Therefore, it would be desirable to have an improved control marker for auto-detection of the control solution and method of using the same.


SUMMARY OF THE INVENTION

According to one method, a control solution is distinguished from a sample during operation of an electrochemical test sensor measuring the amount of an analyte in the control solution and in the sample. A control marker is added to the control solution. The control marker is adapted to be electrochemically oxidized at a potential higher than the potential needed to measure the oxidation of the analyte. The control marker includes sodium iodide, triethanolamine, tripropanolamine, tributanolamine, 2,5-dihydroxybenzoic acid, xylenol orange, hydroquinone sulfonic acid, cresol red, 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid, N-acetyl-5-aminosalicyclic acid, N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid (TOOS), 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 2-napthylamine 1-sulfonic acid, sodium diphenylamine-4-sulfonate, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), or salts thereof. The control solution, the control marker and a predetermined amount of the analyte is introduced to the electrochemical test sensor. The test sensor includes a working electrode, a counter electrode and a reagent. A potential is applied at least once to the test sensor sufficient to oxidize the control marker and the analyte. The resulting electrical current is measured. A potential is applied at least once to the electrochemical test sensor in which the potential is sufficient to measure oxidation of the analyte and not sufficient to oxidize the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents is then performed.


According to one embodiment, a control solution for use in testing an electrochemical system for measuring the amount of an analyte in a sample includes a predetermined amount of the analyte and a predetermined amount of a control marker. The control marker is adapted to be oxidized at a potential higher than the potential required to oxidize the analyte. The control marker includes sodium iodide, triethanolamine, tripropanolamine, tributanolamine, 2,5-dihydroxybenzoic acid, xylenol orange, hydroquinone sulfonic acid, cresol red, 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid, N-acetyl-5-aminosalicyclic acid, N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid (TOOS), 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 2-napthylamine 1-sulfonic acid, sodium diphenylamine-4-sulfonate, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), or salts thereof. The predetermined amount of the control marker is proportional to the predetermined amount of analyte such that the presence of the control marker is detectable.


According to another method, a control solution is distinguished from a sample during operation of an electrochemical test sensor in which the electrochemical test sensor measuring the information related to an analyte. A control solution is provided including a control marker and a predetermined amount of analyte. The control marker has a higher potential than the potential needed to measure the oxidation of the analyte. The control marker includes sodium iodide, triethanolamine, tripropanolamine, tributanolamine, 2,5-dihydroxybenzoic acid, xylenol orange, hydroquinone sulfonic acid, cresol red, 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid, N-acetyl-5-aminosalicyclic acid, N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid (TOOS), 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 2-napthylamine 1-sulfonic acid, sodium diphenylamine-4-sulfonate, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), or salts thereof. An electrochemical sensor having a working electrode, a counter electrode and a reagent is provided. The control solution is introduced to the electrochemical test sensor. A potential is applied to the electrochemical test sensor sufficient to oxidize the control marker and the analyte. The resulting electrical current is measured. A lower potential is applied to the electrochemical test sensor in which the lower potential is sufficient to oxidize the analyte and not sufficient to oxidize the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents is then performed.


According to a further method, a control solution is distinguished from a sample during operation of an electrochemical test sensor measuring the amount of an analyte in the control solution and in the sample. A control marker is added to the control solution. The control marker is adapted to be electrochemically oxidized at a potential higher than the potential needed to measure the oxidation of the analyte. The control solution, the control marker and a predetermined amount of the analyte are introduced to the electrochemical test sensor. The test sensor includes a working electrode, a counter electrode and a reagent. The control solution includes a sufficient amount of anionic polymer to increase the electrical current by at least 5% as compared to a control solution in the absence of an anionic polymer. A potential is applied at least once to the test sensor sufficient to oxidize the control marker and the analyte. The resulting electrical current is measured. A potential is applied at least once to the electrochemical test sensor lower than the previous potential. The potential is sufficient to measure oxidation of the analyte and not sufficient to oxidize the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents.


According to yet another method, a control solution is distinguished from a sample during operation of an electrochemical test sensor measuring the amount of an analyte in the control solution and in the sample. The control marker is then added to the control solution. The control marker is adapted to be electrochemically oxidized at a potential higher than the potential needed to measure the oxidation of the analyte. The control solution, the control marker and a predetermined amount of the analyte are introduced to the electrochemical test sensor. The test sensor includes a working electrode, a counter electrode and a reagent. The control solution includes a sufficient amount of salt to increase the electrical current by at least 5% as compared to a control solution in the absence of a salt to increase the measured current. A potential is applied at least once to the test sensor sufficient to oxidize the control marker and the analyte. The resulting electrical current is measured. A potential is applied at least once to the electrochemical test sensor lower than the previous potential. The potential is sufficient to measure oxidation of the analyte and not sufficient to oxidize the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents is then performed.


According to another method, the concentration of an analyte in a fluid sample is determined. The fluid sample is introduced to a test sensor. At least transferring one electron from the analyte in the sample to a mediator in the test sensor. A pulse sequence is applied to the sample. The pulse sequence includes at least two duty cycles within 180 seconds. At least one of the duty cycles having a first potential in a first excitation period and a first relaxation period. After one of the duty cycles, providing a second potential to the sample. The second potential is greater than the first potential. The second potential is supplied after a second relaxation period. The second relaxation period is less than the first relaxation period. Analyzing a current responsive to the excitation of the measurable species. Determining whether a control solution or a sample is present based on the measured electrical currents is then performed.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a test sensor according to one embodiment.



FIG. 1B is a side view of the test sensor of FIG. 1A.



FIG. 2 is one plot of potential versus time for a burn period.



FIG. 3 is one plot of current versus time for the potential applied as FIG. 2.



FIG. 4 is a plot of current versus time using gated amperometry according to one method.



FIG. 5 is a cyclic voltammogram described in Example 1.



FIG. 6 is a cyclic voltammogram described in Example 2.



FIG. 7 is a cyclic voltammogram described in Example 3.



FIG. 8 is a cyclic voltammogram described in Example 4.



FIG. 9 is a cyclic voltammogram described in Example 5.



FIG. 10 is a plot of current versus time obtained in Example 6.



FIG. 11 are cyclic voltammograms described in Example 7.



FIG. 12 is a cyclic voltammogram described in Example 8.



FIG. 13 is a cyclic voltammogram described in Example 9.



FIG. 14 is a cyclic voltammogram described in Example 10.



FIG. 15 is a cyclic voltammogram described in Example 11.



FIG. 16 is a cyclic voltammogram described in Example 12.



FIG. 17 is a plot of NaCl with a control marker described in Example 14.



FIGS. 18A, 18B are plots of control solutions and blood solutions described in Example 15.



FIG. 19 is a cyclic voltammogram described in Example 16.





DETAILED DESCRIPTION OF ILLUSTRATED EMBODIMENTS

The present invention is directed to a control marker (also referred to as an internal reference) and a method of using the same. A control marker is an additive to a liquid control solution. The control marker is configured to generate a distinctive current profile using a detection algorithm. By having a distinctive current profile, the meter or instrument can automatically distinguish a control test from an analyte-fluid test (e.g., a glucose blood sample).


The control marker is used in an electrochemical test sensor that is adapted to assist in determining information related to an analyte, such as an analyte concentration. The electrochemical test sensors are adapted to receive a fluid sample and be analyzed using an instrument or meter. The electrochemical test sensor assists in determining information related to the analytes such as analyte concentrations. Analytes that may be measured include glucose, cholesterol, lipid profiles, microalbumin, urea, creatinine, creatine, fructose, lactate, or bilirubin. It is contemplated that other analyte concentrations may be determined. The analytes may be in, for example, a whole blood sample, a blood serum sample, a blood plasma sample, other body fluids like ISF (interstitial fluid) and urine, and non-body fluids.


The test sensors described herein are electrochemical test sensors. Meters used with the electrochemical test sensors may have optical aspects so as to detect the calibration information and electrochemical aspects to determine the information related to the analyte (e.g., analyte concentration of the fluid sample). One non-limiting example of an electrochemical test sensor is shown in FIG. 1A. FIG. 1A depicts a test sensor 10 including a base 11, a capillary channel, and a plurality of electrodes 16 and 18. A region 12 shows an area that defines the capillary channel (e.g., after a lid is placed over the base 11). The plurality of electrodes includes a counter electrode 16 and a working (measuring) electrode 18. The electrochemical test sensor may also contain at least three electrodes, such as a working electrode, a counter electrode, a trigger electrode, or a hematocrit electrode. The working electrode employed in electrochemical test sensors according to the embodiments of the present invention may vary, with suitable electrodes including, but not limited to, carbon, platinum, palladium, gold, ruthenium, rhodium and combinations thereof.


The electrodes 16, 18 are coupled to a plurality of conductive leads or traces 15a,b, which, in the illustrated embodiment, terminates with larger areas designated as test-sensor contacts 14a,b. The capillary channel is generally located in a fluid-receiving area 19. It is contemplated that other electrochemical test sensors may be used with the control markers discussed in the present invention.


The fluid-receiving area 19 includes at least one reagent for converting the analyte of interest (e.g., glucose) in the fluid sample (e.g., blood) into a chemical species that is electrochemically measurable, in terms of the electrical current it produces, by the components of the electrode pattern. The reagent typically includes an analyte-specific enzyme that reacts with the analyte and with an electron acceptor to produce an electrochemically measurable species that may be detected by the electrodes. Enzymes that may be used with glucose include glucose oxidase and glucose dehydrogenase. If information of another analyte is desired, an appropriate enzyme is selected to react with the analyte. One non-limiting example in detecting glucose includes using an enzyme of glucose oxidase, a mediator of a ferricyanide salt and buffer to maintain a pH of from about 5 to about 7. Another non-limiting example in detecting glucose includes using an enzyme of glucose dehydrogenase, a co-factor such as pyrroloquinoline quinone (PQQ), and a buffer to maintain a pH of from about 6 to about 8.


The reagent typically includes a mediator that assists in transferring electrons between the analyte and the electrodes. The reagent may include binders that hold the enzyme and mediator together, other inert ingredients, buffers or combinations thereof.


A fluid sample (e.g., blood) may be applied to the fluid-receiving area 19. The fluid sample reacts with the at least one reagent. After reacting with the reagent and in conjunction with the plurality of electrodes, the fluid sample produces electrical signals that assist in determining the analyte concentration. The conductive leads 15a,b carry the electrical signal back toward a second opposing end 42 of the test sensor 10 where the test-sensor contacts 14a,b transfer the electrical signals into the meter.


Referring to FIG. 1B, a side view of the test sensor 10 of FIG. 1A is shown. As shown in FIG. 1B, the test sensor 10 of FIG. 1B further includes a lid 20 and a spacer 22. The base 11, the lid 20, and the spacer 22 may be made from a variety of materials such as polymeric materials. Non-limiting examples of polymeric materials that may be used to form the base 11, the lid 20, and the spacer 22 include polycarbonate, polyethylene terephthalate (PET), polyethylene naphthalate (PEN), polyimide, and combinations thereof. It is contemplated that other materials may be used in forming the base 11, lid 20, and/or spacer 22.


To form the test sensor 10 of FIGS. 1A, 1B, the base 11, the spacer 22, and the lid 20 are attached by, for example, an adhesive or heat sealing. When the base 11, the lid 20, and the spacer 22 are attached, the fluid-receiving area 19 is formed. The fluid-receiving area 19 provides a flow path for introducing the fluid sample into the test sensor 10. The fluid-receiving area 19 is formed at a first end or testing end 40 of the test sensor 10. Test sensors of the embodiments of the present invention may be formed with a base and a lid in the absence of a spacer, where the fluid-receiving area is formed directly in the base and/or the lid.


It is also contemplated that the electrochemical test sensor may be formed in the absence of a spacer. For example, the electrochemical test sensor may include a base and a lid such that a channel (e.g., capillary channel) is formed when the base and the lid are attached to each other.


The base, spacer and lid may be made from a variety of materials such as polymeric materials. Non-limiting examples of polymeric materials that may be used to form the base, spacer and lid include polycarbonate, polyethylene terephthalate (PET), polystyrene, polyimide, and combinations thereof. It is contemplated that the base, spacer and lid may be independently made of other materials. Depending on the selected control solutions, the electrode pattern may be made from a variety of conductive materials including, but not limited to, gold, platinum, rhodium, palladium, ruthenium, carbon or combinations thereof. Carbon electrodes may be desirable depending on the selected control solution.


In one method, an electrochemical test sensor for measuring an analyte in a fluid (e.g., glucose in a whole blood sample), the working and counter electrodes are coated with reagent by, for example, co-printing or co-depositing. The reagent typically includes some polymers and the reactive ingredients. Some reactive ingredients include an enzyme that oxidizes the analyte (e.g., glucose) in the fluid sample and a mediator, which is a redox compound that re-oxidizes the enzyme after it has been reduced by oxidizing analyte. The reduced mediator carries electrons from the enzymatic reaction of glucose oxidation to the working electrode and is re-oxidized at the electrode surface. The applied voltage differential between the two electrodes results in the mediator passing electrons to the working electrode, creating a measurable current that is proportional to the amount of glucose in the sample. The test sensor also may comprise single or multiple reagent layers, or may comprise different single or multiple reagent layers at each electrode, working and counter electrodes.


Electrochemical test sensors and, more specifically, amperometric test sensors apply a fixed potential across the electrodes and the current produced is measured over a predetermined period of time (e.g., 5 or 10 seconds) to correct for the bias that may be present due to premature reduction of the mediator. In one system, a potential is applied for two periods of time, separated by a resting period. A typical plot of the potential versus time for the first or “burn period” is presented in FIG. 2. FIG. 3 shows a typical plot of current versus time. The current rises to a peak while the sample is rehydrating the reagent layer, enabling the oxidation and reduction reactions to occur and then declines as diffusion begins to control. After this brief period, the applied potential is removed or at least reduced during a resting period, while the oxidation of glucose and reduction of the mediator continue. Then, the potential is reapplied for a second period and the current measured over the “read” period (e.g., 10 seconds). Since reduced mediator is present as the result of the concomitant oxidation of the enzyme, the current produced initially is high, but then it declines rapidly and approaches a steady state diffusion-controlled condition. The current recorded at the end of the short “read” period is used to determine the glucose content of the blood sample, through a previously obtained correlation between the current at the end of the read period and the glucose contained in test samples having known concentrations.


As discussed above, it is highly desirable for the control solution to provide accurate analyte readings and be distinguishable from a biological sample. The present invention employs an oxidizable species (i.e., a control marker) that is oxidizable only at voltages higher than those used for the analyte (e.g., glucose) measurements. This means that at a low potential adequate to fully oxidize the analyte-related mediator, but not the control marker, only the analyte will be measured. The term control marker is also referred to as an internal reference. When the potential is high enough to oxidize the added control marker, both the analyte and the control marker will be oxidized. Although the analyte (e.g., glucose) is oxidized at the higher potential, the measurement made at a lower voltage is already diffusion-limited and does not depend on the total amount of analyte oxidized by the enzyme. It is feasible, therefore, to add such control markers to a control solution and to use it to identify the solution as a control and not as a biological sample.


The control markers to be used include the following: sodium iodide, triethanolamine, tripropanolamine, tributanolamine, 2,5-dihydroxybenzoic acid, xylenol orange, hydroquinone sulfonic acid, cresol red (C21H17NaO5S), and salts thereof.


Other non-limiting examples of control markers and their derivates include 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid, N-acetyl-5-aminosalicyclic acid, N-ethyl-N-(3-sulfopropyl)-3-methylaniline (also referred to as TOPS), 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid (also referred to as TOOS), 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 2-napthylamine 1-sulfonic acid, sodium diphenylamine-4-sulfonate, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (also referred to as MAOS), and salts thereof. It is desirable that the control markers and their derivatives thereof have sufficient stability and solubility in the control solution as well as having an oxidizing potential in a desired range.


In one method, the sodium iodide may be used in combination with a phenothiazine mediator or phenoxazine mediator such as, for example, 3-(2′,5′-disulfophenylimino)-3H-phenothiazine mediator. It is also contemplated that the control markers of 2,5-dihydroxybenzoic acid, xylenol orange, hydroquinone sulfonic acid and cresol red may also be used with a phenothiazine mediator or phenoxazine mediator such as, for example, 3-(2′,5′-disulfophenylimino)-3H-phenothiazine. In one method, the triethanolamine may be used in combination with a ferricyanide-based mediator such as potassium ferricyanide. It also contemplated that the control markers of tripropanolamine and tributanolamine may be used in combination with a ferricyanide-based mediator such as potassium ferricyanide. It is contemplated that the above-identified controls makers may be used with other mediators.


In another method, 3-(2′,5′-disulfophenylimino)-3H-phenothiazine may be used as a mediator with the following control markers: 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid, N-acetyl-5-aminosalicyclic acid, N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid (TOOS), 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 2-napthylamine 1-sulfonic acid, sodium diphenylamine-4-sulfonate or N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), and salts thereof. It is contemplated that other compounds may be used as a mediator for these control markers and their derivatives including, for example, ferricyande, especially using the higher voltage potential compounds.


The difference between the currents measured at high and low voltages may be compared to indicate the presence of the internal reference characteristic of the control solution. In one non-limiting method, a Differential Index (DI) may be employed following current components relating to the analtye (e.g., glucose) and the control marker:

DI=ihigh volt/ilow volt=(iint ref+iglucose)/iglucose=1+iint ref/iglucose

where ihigh volt is the current measured at the higher voltage

    • ilow volt is the current measured at the lower voltage


It follows that if the control marker is not present (such as in the blood samples), iint ref should be zero and the ihigh volt will be substantially the same as ilow volt. Thus, the DI value will typically approach 1 when the control marker is not present. The DI value in practice, however, may have values over 1 when the control marker is not present, especially when a lower glucose concentration is measured during a change from a low voltage to a higher voltage. In such a scenario, the control marker may have a higher DI than 1.


When the control marker is present, the value of DI will be greater than 1, depending on the amount of the control marker relative to the amount of analyte. If the amount of control marker added to the control solution provides a current similar to that from oxidizing the analyte-related mediator, the DI value may be generally about two times that from oxidizing the analyte-related mediator. The control marker may be included in an amount suitable for control solutions corresponding to a high analyte concentration.


It is typical to use several control solutions corresponding to low, normal, and high analyte concentration to test a glucose meter. If, for example, the amount of the control marker is chosen so that the DI value is 1.75 or greater for the highest analyte concentration in the control solution, the current from the control marker will be relatively large compared to the current for the analyte in the lowest analyte control solution. Then the same amount of the control marker used with a control solution having a low analyte concentration will provide an even higher value of DI. Such high DI values will provide higher confidence in the presence of a control solution, rather than a biological sample (e.g., whole blood). Clearly, a quantitative index such as the DI value has an advantage over the more qualitative methods of relying on the shape of the current versus time curve in the burn or read periods. The addition of a control solution oxidized at a higher voltage provides a result that is independent of the enzymatic reaction and the composition of the control solution.


In one embodiment, the amount of the control marker added to the control solution is related to the amount of analyte present. That is, the amount of the control marker in the control solution is proportional to the analyte concentration to maintain an approximately constant DI value. One method uses enough control marker to provide a DI of about 1.5 or higher when the maximum amount of an analyte (e.g., using about 300 mg/dL of glucose) is used. Then, the amount of the control marker is reduced so that control solutions containing lower analyte concentrations maintain a DI value of 1.5 or higher.


Adding a control marker to control solutions makes it possible to readily distinguish between control solutions and biological samples, and provides improved accuracy of the analysis. The above-identified control markers are oxidizable electrochemically at a desirable potential. It is important to understand that not all compounds oxidizable chemically are oxidizable electrochemically at an appropriate potential or at any oxidizable potential.


Other additives may include buffers, polymers, salts, dyes, anti-microbial agents, thickening agents, and surfactants. It is contemplated that other additives may be used.


The pH of the control solution is an important factor in the reaction in which glucose is oxidized by an enzyme, such as glucose oxidase. For the measurement of glucose, a pH of about 5 to about 7 is desirable when glucose oxidase is used, while a pH of about 6 to about 8 is preferred when glucose dehydrogenase used. A buffer is usually provided to assure that the oxidation of glucose proceeds at the expected rate. It is advantageous that the control marker and the buffer are separate components, with each serving a different function, thus enabling the optimization of each function (buffer and control marker) separately. The buffers may be chosen from those compatible with the enzymatic reagent. Examples include, but are not limited to, citrate buffer, phosphate buffer and amine-based buffers (e.g., HEPES, MOPS, TES, bis-Tris and Tris). It is contemplated that other buffers may be used.


The polymeric materials used to mimic the blood's fluidic properties may include polyethylene oxide, polyhydroxyethyl methacrylate, polyvinylpyrrolidone (PVP), Xanthan gum, in amounts of from about 0.5 or 1.0 to about 25 wt. %. The glucose is typically present in control solutions in the amounts equivalent to about 30 to 400 mg/dL, a range that spans the expected glucose content of blood samples.


It is contemplated that an anionic polymer may be added to the control solution as an additive. When a control marker includes an anionic polymer, it generates a much higher current signal than a non-ionic polymer. By having a higher current signal, better differentiation of the control solution from the fluid sample (e.g., blood) is obtained. Additionally, by having a higher current signal, the costs of the control solution is reduced because less control marker is needed.


Some non-limiting examples of anionic polymers that may be used in a control solution include carboxylic acids, sulfonic acids, phosphoric acids and salts of the same. Non-limiting examples of carboxylic acids include polyacrylic acid (PAA), polymaleic acid, carboxymethyl cellulose (CMC), an alternating methylvinylether/maleic anhydride copolymer such as Gantrez® from International Specialty Products, copolymers or salts thereof. Non-limiting examples of sulfonic acids include polystyrene sulfonic acid, polyvinyl sulfonic acid (PVS), copolymers or salts thereof. Non-limiting examples of phosphoric acids that may be used include polyvinylphosphoric acid, polyvinylphosphoric sodium salt, polyvinylphosphoric potassium salt, copolymers and salts thereof. The amount of polymeric charge in the anionic polymer is related to the structure of the polymer and also the amount of polymer in the control solution.


It is also contemplated that the anionic polymer may be included in the reagent on the test sensor in addition to, or instead of, being located in the control solution.


It is contemplated that a salt may be added to the control solution in an amount that increases the measured current of the control marker significantly. By increasing the current of the control marker, the differentiation between the control solution and the fluid sample (e.g., blood) is improved. Additionally, by increasing the current of the control marker, the amount of the control marker needed is reduced, which reduces the cost.


Some non-limiting examples of salts that may be contained in the control solution include chloride salts, phosphate salts, nitrate salts and sulfate salts. Non-limiting examples of chloride salts include sodium chloride, potassium chloride, ammonium chloride and calcium chloride. Non-limiting examples of phosphate salts include sodium phosphate, potassium phosphate, ammonium phosphate and calcium phosphate. Non-limiting examples of nitrate salts include sodium nitrate, potassium nitrate, ammonium nitrate and calcium nitrate. Non-limiting examples of sulfate salts include sodium sulfate, potassium salt, ammonium salt and calcium sulfate. It is contemplated that other salts may be used to increase the current of the control markers such as sodium acetate, sodium citrate and sodium succinate.


The control solution includes a sufficient amount of anionic polymer to increase the electrical current by at least 5% as compared to a control solution in the absence of an anionic polymer. It is desirable for the control solution to include a sufficient amount of anionic polymer to increase the electrical current by at least 10 or 20% as compared to a control solution in the absence of an anionic polymer. It is even more desirable for the control solution to include a sufficient amount of anionic polymer to increase the electrical current by at least 40 or 50% as compared to a control solution in the absence of an anionic polymer.


It is contemplated that an anionic polymer may be used with the salts in the control solution to increase the measured current of the control marker significantly.


By introducing a control marker oxidizable at a higher voltage than is used to oxidize the analyte-related mediator, it is necessary to apply the higher voltage at some point during the measurement protocol. Where two periods are used as described above in connection with FIGS. 2 and 3 (the “burn” and “read” periods), various combinations of potential steps within and across the burn and read periods may be used to provide both a DI value identifying the control solution and a current from which the analyte content of the control solution could be determined. In one method, a high voltage is applied during the burn period and a low voltage is applied during the read period. Thus, the Differential Index is:

DI=iburn/iread


When the control marker is present, the current measured during the burn period includes the current resulting from oxidization of the control marker plus the current resulting from oxidizing the analyte-related mediator. The current measured during the read period results only from oxidation of the analyte, since the voltage would be too low to oxidize the control marker. Thus, the ratio of burn current to read current reflects the value of the control marker current against the current of the analyte measurement.


Alternatively, both high and low voltages may be applied during the burn period to detect the presence of the control marker, while only a low voltage is used during the read period. This combination of potential steps still maintains the working principle of taking the ratio of the current from a high voltage to that from a low voltage. A distinct change in the current would be seen when a change is made from a low voltage to a high voltage, or vice versa. The low voltage need not be identical with that used in the read period to measure analyte. The comparative voltage may be merely lower than needed to oxidize the control marker. Since the burn period corresponds to a time when the sample is hydrating the reagents, the current may change during the burn period, as suggested in the generic diagram of FIG. 3. Consequently, it may be advantageous to make more than one excursion between high and low voltages to assure that the DI values are not affected by changes in the reagent availability during the burn period.


In another alternative method, a high voltage (i.e., one that oxidizes the control marker) is used during a portion of the read period. Thus, the DI may be determined during the read period by measuring the high and low currents only during the read period. This method may be advantageous in that any variation in reagent availability seen in the burn period is avoided. Again, using more than one excursion between low and high voltages may be advantageous.


In another method, frequent cycling of potential between high and low voltages is used to affect the shape of the current versus time during the read period, which is shown generically in FIG. 3. The curve typically shows a rapid decay of the current caused by the depletion of the reduced mediator at and near the electrode surface. Thus, the total analyte (e.g., glucose) content is determined by correlation with the diffusion-limited current, rather than measuring the total analyte in the control solution. It is evident that the time chosen as a measure of the glucose is important if consistent and accurate measurements are to be obtained.


The control solutions of the present invention include a control marker that is oxidized electrochemically at a potential greater than that needed to oxidize the analyte and also includes a predetermined amount of analyte. Since, for example, oxidation of the glucose-related mediator (e.g., potassium ferricyanide) requires a potential of 200 mV relative to the potential at the counter electrode of ferricyanide, the oxidation potential for the control marker should be at least 200 mV and more desirably at least 300 mV greater relative to the same counter electrode.


One method of examining the effect of adding a control marker to control solutions is using cyclic voltammetry. Instead of applying a fixed potential, a varying voltage is used, sweeping from negative to positive relative to the counter electrode.


Another method of examining the effect of adding a control marker to control solutions is gated amperometry that uses pulses. The use of a gated amperometric pulse sequence may include multiple duty cycles that may provide improved accuracy and precision to an analysis, while reducing the completion time of the analysis.


One especially desirable gated amperometric method that may be used with the control markers identified above—sodium iodide, triethanolamine, tripropanolamine, tributanolamine, 2,5-dihydroxybenzoic acid, xylenol orange, hydroquinone sulfonic acid and cresol red—is shown in relation to FIG. 4. It is contemplated that this gated amperometric method may be used with other control markers identified above such as 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid, N-acetyl-5-aminosalicyclic acid, N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid (TOOS), 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 8-anilino-1-naphthalenesulfonic acid, 2-napthylamine 1-sulfonic acid, sodium diphenylamine-4-sulfonate, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), and salts thereof.



FIG. 4 shows one non-limiting example of such a desirable gated amperometric method. Specifically, in this method, at the end of the assay, a high voltage is raised at the end of the assay potential sequence. For example, FIG. 4 shows a high voltage segment 210 (600 mV) connected to a normal voltage pulse 220 (200 mV). Before this high voltage is raised, a separate short delay or relaxation period 230 for the control marker. This is shown at a time of from about 6 to about 7 seconds in FIG. 4. By having a separate short delay or relaxation period, this assists in reducing the likelihood to consume the reduced form of the mediator, which may result in the control markers having a lower current than expected. By having this relaxation period, the current of the control solution will have desirably higher currents that will better assist in differentiating the control solution and the actual analyte readings.



FIG. 4 depicts pulse sequences that include an initial cycle 240 followed by four duty cycles 250, 260, 270, 220 having the same excitation and open circuit delay times in addition to a terminal read pulse of longer duration that increases in voltage after a very short relaxation period. A duty cycle is defined herein as having a relaxation period followed by voltage pulse. The increased voltage of this terminal read pulse provides the ability to detect a species having a higher oxidation potential.


In this particular gated amperometric method, the analyte is measured by (a) applying a first potential sufficient to oxidize the analyte for a first predetermined period of time, followed by (b) applying pulsed second potentials insufficient to oxidize the analyte and lower than the first potential for a second predetermined period of time, and followed by (c) applying a third potential higher than the second potential and sufficient to oxidize the analyte for a third predetermined period of time. This third potential is applied after a very short relaxation period after, for example, one of the second potentials was applied.


Thus, in the FIG. 4 method, each duty cycle includes an excitation that may be provided at a relatively constant voltage. Each duty cycle also includes a relaxation period 280 that may be provided by an open circuit. The pulse sequences may reduce the time required for analysis by eliminating the need for additional delays and pulses, such as “incubation” delays to provide reagent rehydration, “burn-off” pulses to renew the electrodes and mediator regeneration pulses to renew the oxidation state of the mediator, thus reducing analysis time.


Even with shorter analysis times, the inventive gated amperometric pulse sequence may improve accuracy and/or precision in relation to conventional methods. In one aspect, errors in performance accuracy introduced by the hematocrit effect and precision introduced by varying cap-gap volume may be reduced with the assistance of the inventive pulse sequence. In another aspect, errors otherwise resulting from a non-steady-state sensor condition and/or mediator background may be reduced. The gated pulse sequences also may allow the determination of transient current and contour profiles that simulate a steady-state condition. The transient current profiles may be used to provide a plurality of sets of calibration constants, under-fill detection, and the ability to determine the temperature of the sample, instead of relying on the temperature from the measuring device.


The duty cycles may vary in the inventive gated amperometric pulse sequence. In one method, 3 to 18 or from 3 to 10 duty cycles are applied within about 30 seconds or less. In another method, from 3 to 8 duty cycles are applied within 3 to 16 seconds.


The potential applied during the excitation portion of the duty cycle is desirably applied at a substantially constant voltage and polarity throughout its duration. This directly contrasts to conventional read pulses where the voltage is changed or “swept” through multiple voltage potentials and/or polarities during data recordation. In one aspect, the duration of the excitation is at most 4 or 5 seconds, and desirably less than 3, 2, 1.5, or 1 second. In another aspect, the duration of the excitation is from 0.01 to 3 seconds, from 0.01 to 2 seconds, or from 0.01 to 1.5 seconds. More desirably, the duration of the excitation is from 0.1 to 1.2 seconds.


After the excitation period, the measuring device may open the circuit through the sensor strip, thus allowing the system to relax. During the relaxation period, the current present during the excitation period is substantially reduced by at least one-half, preferably by an order of magnitude, and more desirably to zero. Desirably, a zero current state is provided by an open circuit or other method known to those of ordinary skill in the art to provide a substantially zero current flow. At least 3 relaxations may be provided during the duty cycles of the pulse sequence.


In one aspect, the relaxation period is at least 10, 5, 3, 2, 1.5, 1, or 0.5 seconds in duration. In another aspect, the relaxation period is from 0.1 to 3 seconds, from 0.1 to 2 seconds, or from 0.1 to 1.5 seconds in duration. More desirably, the relaxation period is from 0.2 to 1.5 seconds in duration and provided by an open circuit.


During the relaxation period, the ionizing agent may react with the analyte to generate additional measurable species without the effects of an electric potential. Thus, for a glucose-sensor system including glucose oxidase and a ferricyanide mediator as reagents, additional ferrocyanide (reduced mediator) responsive to the analyte concentration of the sample may be produced without interference from an electric potential during the relaxation period.


According to another method, a control marker differentiation method is based on both DI discussed above and the current of the control marker. As discussed above, DI is as follows:

DI=ihigh volt/ilow volt=(iint ref+iglucose)/iglucose=1+iint ref/iglucose

    • where ihigh volt is the current measured at the higher voltage
      • ilow volt is the current measured at the lower voltage


        The benefit of using both DI and the current of the control marker is to obtain better differentiation of the control solution and the fluid sample (e.g., blood sample) with very low glucose concentrations. Because blood samples with low glucose have a higher DI, they are more difficult to differentiate from the control marker when only DI is used.


In this method, the control current is checked after a certain time period (e.g., after 5 seconds at a current of 0.6V), which may be referred to as ihigh volt. If the current is less than a selected value (e.g., 12,000 nA), then the sample is blood. If the current is greater than the selected value, DI is calculated. If DI is above a certain number (e.g., 1.3), then the sample being tested is a control solution and, if not, the sample is a blood sample. The DI uses a current measurement at a higher voltage and a lower voltage. At the lower voltage, only the current from the mediator being reduced is measured. At the higher voltage, the current from both the control marker and the mediator is measured.


EXAMPLES

The following examples illustrate the concept and application of control markers and its method for auto-detection of control solutions.


Example 1


FIG. 5 showed the current plotted versus the potential as the potential difference was cycled between −300 mV and +800 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 5, Traces 1-4 represented the cyclic voltammograms of sodium iodide (NaI) from a solution running at the 3-(2′,5′-disulfophenylimino)-3H-phenothiazine-based sensor. This sensor had the above mediator deposited on both the working and counter electrodes. When there is no NaI in the solution feeding to the sensor, the cyclic voltammogram resulted from the mediator. Otherwise, the cyclic voltammogram was the sum of both the mediator (appears at lower potential) and the control marker NaI.


Trace 1 included 0 mg/dl of glucose, while Trace 2 used 350 mg/dl of glucose. There were no control markers used in Traces 1 and 2. As shown in FIG. 5, there were no additional oxidation peaks in Traces 1 and 2 after the initial oxidation started at about 0 volts. Traces 3 included 0 mg/dL of glucose and 50 mV NaI as the control marker, while Trace 4 used 350 mg/dl of glucose and 50 mV NaI. Traces 3 and 4 represented the oxidation wave of NaI in the solution. Both of the measured currents peaked in the potential range between about 500 and 600 mV for Traces 3 and 4. As shown in FIG. 5, there was no oxidation current from the NaI in the potential range of 100 to 300 mV. Thus, a low voltage at a potential in the range of about 200 to 300 mV for the mediator (3-(2′,5′-disulfophenylimino)-3H-phenothiazine) and a high voltage at a potential range in the range of about 500 to 600 mV for the control marker (NaI) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 2


FIG. 6 showed the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 6, Trace 1 and 2 represented cyclic voltammograms of triethanolamine (TEA) and ferricyanide in a potassium ferricyanide-based glucose mediator. The sensor with ferricyanide mediator was manufactured with deposition of mediator ferricyanide, enzyme, polymer and other ingredients. Trace 1 included 75 mg/dl of glucose, but did not use a control marker. As shown in FIG. 6, there was an apparent peak in Trace 1 around 0 mV, but no oxidation peak at 600 mV. In addition to the 75 mg/dL of glucose, Trace 2 further included 50 mV triethanolamine as the control marker or the internal reference. In contrast to Trace 1, Trace 2 with the triethanolamine had a cyclic voltammogram that displayed oxidation currents of various magnitudes of 400 mV and greater. See FIG. 6. Thus, since the peak at 0 mV is well separated from the currents using triethanolamine, a low voltage having a potential in the range of about 200 mV to 300 mV for the mediator (potassium ferricyanide) and a high voltage at a potential of about 600 mV for the control marker (triethanolamine) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 3


FIG. 7 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 7, Traces 1-3 represented cyclic voltammograms of three control markers from a solution running at the 3-(2′,5′-disulfophenylimino)-3H-phenothiazine-based sensor. This sensor has the above mediator deposited on both the working and counter electrodes from manufacturing. Each trace contained the oxidation of both the reduced mediator and the control marker. Trace 1 further included 50 mV of 2,5-dihydroxybenzoic acid at pH 7 as the control marker. Trace 2 further included 50 mV of xylenol orange at pH 7 as the control marker. Trace 3 further included 50 mV of hydroquinone sulfonic acid at pH 7 as the control marker.


Referring still to FIG. 7, the small redox waves near 0 mV corresponded with the oxidation of the 3-(2′,5′-disulfophenylimino)-3H-phenothiazine mediator in the electrochemical test sensors. This was also shown in Traces 1 and 2 of FIG. 5 that were discussed above. Referring back to FIG. 7, the oxidation potentials of each of the three chemical species (2,5-dihydroxybenzoic acid, xylenol orange and hydroquinone sulfonic acid) were about 400 to 600 mV higher as shown in FIG. 7 by respective Traces 1-3. Thus, a low voltage at a potential of about 200 mV for the mediator (3-(2′,5′-disulfophenylimino)-3H-phenothiazine) and a high voltage at a potential in the range of about 600 to 800 mV for the control markers (2,5-dihydroxybenzoic acid, xylenol orange and hydroquinone sulfonic acid) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 4


FIG. 8 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 8, Trace 1 represented the cyclic voltammogram of tripropanolamine (TPA) and ferricyanide in the potassium ferricyanide-based sensor. The sensor with ferricyanide mediator was manufactured with deposition of mediator ferricyanide, enzyme, polymer and other ingredients. The small redox waves near 0 mV indicated that the oxidation of ferrocyanide and the reduction of ferricyanide in the sensor. This was also shown in Trace 1 of FIG. 6 that was discussed above. Referring back to FIG. 8, the oxidation potential of the chemical species (tripropanolamine) was about 600 to 700 mV higher than ferricyanide as shown in FIG. 8 by Trace 1. Thus, a low voltage at a potential of about 200 mV for the mediator (ferricyanide) and a high voltage at a potential in the range of about 600 to 700 mV for the control marker (tripropanolamine) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 5


FIG. 9 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,200 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 9, Traces 1 and 2 represented cyclic voltammograms of Cresol Red from a solution running at the 3-(2′,5′-disulfophenylimino)-3H-phenothiazine-based sensor. This sensor has the above mediator deposited on both the working and counter electrodes from manufacturing. When there is no Cresol Red in the solution feeding to the sensor, the cyclic voltammogram resulted from the mediator. Otherwise, the cyclic voltammogram is the sum of both the mediator (appears at lower potential) and the control marker Cresol Red. Trace 1 included 3-(2′,5′-disulfophenylimino)-3H-phenothiazine mediator, but did not include a control marker or internal reference. Trace 2 included 3-(2′,5′-disulfophenylimino)-3H-phenothiazine mediator and included 100 mV of cresol red.


Referring still to FIG. 9, the small redox waves near 0 mV corresponded with the oxidation of the 3-(2′,5′-disulfophenylimino)-3H-phenothiazine mediator in the electrochemical test sensors. This was also shown in Traces 1 and 2 of FIG. 5 that were discussed above. Referring back to FIG. 9, the oxidation potential of the cresol red was about 400 to 600 mV higher as shown in FIG. 9 by comparing respective Traces 1 and 2. Thus, a low voltage at a potential of about 200 mV for the mediator (3-(2′,5′-disulfophenylimino)-3H-phenothiazine) and a high voltage at a potential in the range of about 400 to 600 mV for the cresol red may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 6

Referring to FIG. 10, a plot of current (in nA) versus time (in seconds) is shown with a solution including a control marker and a solution that does not include control marker. An aqueous solution containing 350 mg/dl glucose (Plot 1) was compared with another solution containing 350 mg/dL glucose and 50 mV sodium iodide (NaI) as the control marker (Plot 2). Each of the solutions contained 100 mV of (2′,5′-disulfophenylimino)-3H-phenothiazine mediator. This mediator was located on both of the counter and working electrodes of the test sensors.


The current applied in FIG. 10 was the same cyclic voltammetry method described as described above with respect to FIG. 4. Specifically, an initial voltage of 400 mV was applied at time 0. This was following by three separate normal pulses of 200 mV was applied at times of about 2.2, 3.5 and 4.8 seconds. At the end of the assay, a high voltage is raised at the end of the assay potential sequence. A normal voltage pulse of 200 mV was applied at about 6.2 seconds following by a very short delay or relaxation period before a high voltage of 600 mV was applied at about 6.3 seconds.


As shown in FIG. 10, the current sequence at the end of the assay showed a much high current for Plot 2 (with sodium iodide) than with Plot 1 (without a control marker). Compare current of 25000 nA of Plot 2 with current of about 11000 nA of Plot 1 at time 6.2 seconds Thus, the use of the control marker of NaI can be differentiated from a solution without the control marker NaI.


Example 7


FIG. 11 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 11, Trace 1 represented the cyclic voltammogram of 50 mV 3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid. The sensor with a (2′,5′-disulfophenylimino)-3H-phenothiazine ferricyanide mediator was manufactured with deposition of the (2′,5′-disulfophenylimino)-3H-phenothiazine mediator, enzyme, polymer and other ingredients. The redox waves near and below 0 mV indicated that the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid) was about 600 to 800 mV higher than the (2′,5′-disulfophenylimino)-3H-phenothiazine as shown in FIG. 11 by Trace 1. Thus, a low voltage at a potential of about 200 mV for the mediator and a high voltage at a potential in the range of about 600 to 700 mV for the control marker (3-[4-(hydroxyphenyl)amino]-3-oxopropanoic acid) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Having a voltage about 0.6V is highly desirable because this differentiates from the mediator's oxidation while still having a lower oxidation potential that reduces the likelihood of oxidizing other components in the fluid (e.g., blood). In other words, the higher the potential, the more likelihood that other components in the fluid will be oxidized.


Still referring to FIG. 11, Trace 2 represented the cyclic voltammogram of 30 mV N-acetyl-5-aminosalicyclic acid (AAS) and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor included the mediator, enzyme, polymer and other ingredients. The small redox waves near 0 mV indicated the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (N-acetyl-5-aminosalicyclic acid) was about 600 to 800 mV higher than the mediator as shown in FIG. 11 by Trace 2. Thus, a low voltage at a potential of about 200 mV for the mediator and a high voltage at a potential in the range of about 600 to 700 mV for the control marker (N-acetyl-5-aminosalicyclic acid) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 8


FIG. 12 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 12, Trace 1 represented the cyclic voltammogram of 50 mV N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS) and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor included the mediator, enzyme, polymer and other ingredients. The small redox waves near 0 mV indicated the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (N-ethyl-N-(3-sulfopropyl)-3-methylaniline) was about 400 to 800 mV higher than the mediator as shown in FIG. 12 by Trace 1. Thus, a low voltage at a potential of about 200 mV for the mediator and a high voltage at a potential in the range of about 400 to 800 mV for the control marker (N-ethyl-N-(3-sulfopropyl)-3-methylaniline) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 9


FIG. 13 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 13, Trace 1 represented the cyclic voltammogram of 50 mV 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid sodium salt (TOOS) and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor was manufactured with deposition of the mediator, enzyme, polymer and other ingredients. The redox waves near 0 mV indicated the oxidation and reduction of the (2′,5′-disulfophenylimino)-3H-phenothiazine in the sensor. The oxidation potential of the chemical species (3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid sodium salt) was about 400 to 800 mV higher than the mediator as shown in FIG. 13 by Trace 1. Thus, a low voltage at a potential of about 200 mV for the mediator and a high voltage at a potential in the range of about 400 to 800 mV for the control marker (3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid sodium salt) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 10


FIG. 14 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 14, Trace 1 represented the cyclic voltammogram of 50 mV 8-anilino-1-naphthalenesulfonic acid and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor was manufactured with deposition of the mediator, enzyme, polymer and other ingredients. The large redox waves near 0 mV indicated the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (8-anilino-1-naphthalenesulfonic acid) was about 250 to 400 mV higher than the mediator as shown in FIG. 14 by Trace 1. Thus, a low voltage at a potential of about 150 mV for the mediator and a high voltage at a potential in the range of about 350 to 400 mV for the control marker (8-anilino-1-naphthalenesulfonic acid) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 11


FIG. 15 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 15, Trace 1 represented the cyclic voltammogram of 50 mV 2-napthylamine 1-sulfonic acid and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor was manufactured with deposition of the mediator, enzyme, polymer and other ingredients. The large redox waves near 0 mV indicated that the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (2-napthylamine 1-sulfonic acid) was about 600 to 800 mV higher than the mediator as shown in FIG. 15 by Trace 1. Thus, a low voltage at a potential of about 200 mV for the mediator and a high voltage at a potential in the range of about 600 to 800 mV for the control marker (2-napthylamine 1-sulfonic acid) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 12


FIG. 16 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 16, Trace 1 represented the cyclic voltammogram of 50 mV sodium diphenylamine-4-sulfonate and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor was manufactured with deposition of the mediator, enzyme, polymer and other ingredients. The large redox waves near 0 mV indicated the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (sodium diphenylamine-4-sulfonate) was about 600 to 800 mV higher than the mediator as shown in FIG. 16 by Trace 1. Thus, a low voltage at a potential of about 300 mV for the mediator and a high voltage at a potential in the range of about 600 to 800 mV for the control marker (sodium diphenylamine-4-sulfonate) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


Example 13

Various examples showing the effect of current measurements with anionic polymers are discussed below. Specifically, the addition of an anionic polymer was shown to increase the current generated by the control solution. First and second solutions of 75 mV 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid sodium salt (TOOS) included a non-ionic polymer-polyvinylpyrrolidone (PVP). A third solution included 11.6 mM of TOOS was included with the anionic polymer polyacrylic acid (PAA). The percentages of the polymers were selected to generally mimic the viscosity of the blood. The voltage was applied in on-off pulse sequences in which the testing period concluded with the voltage being raised to 0.6V.












TABLE 1








Current @


Solution #
Control Solution
Polymer
0.6 V (nA)







1
75 mM TOOS
1.7% PVP 10K
16,518


2
75 mM TOOS
6% PVP 6K
17,867


3
11.6 mM TOOS
18.7% PAA 3K
21,597









As shown in Table 1, despite having a TOOS concentration over 6 times greater, Solutions 1 and 2 without an anionic polymer had a lower current than Solution 3, which included the anionic polymer PAA.


Table 2 below shows various currents that were measured at 0.6V (nA) with various solutions. The voltage was applied in on-off pulse sequences in which the testing period concluded with the voltage being raised to 0.6V. The pulse sequences were the same for the testing of each of the solutions. Solutions 4 and 5 included a non-ionic polymer-polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP), respectively. Solutions 6 and 7, on the other hand, included an anionic polymer-polyvinyl sulfonic acid (PVS) and polyacrylic acid (PAA), respectively. The percentages of the polymer were selected to generally mimic the viscosity of the blood. Solutions 4-7 each included 10 mV of 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid sodium salt (TOOS).












TABLE 2








Current @


Solution #
Control Solution
Polymer
0.6 V (nA)


















4
10 mM TOOS
6% PVA 6K
8,500


5
10 mM TOOS
2.3% PVP 55K
7,000


6
10 mM TOOS
17.6% PVS
15,500


7
10 mM TOOS
18.7% PAA 3K
16,000









As shown in Table 2, using the same amount of TOOS, Solutions 6 and 7 with an anionic polymer had much higher currents than Solutions 4 and 5, which did not include an anionic polymer. Compare 15,500 and 16,000 nA of Solutions 6 and 7 with 8,500 and 7,000 nA of Solutions 4 and 5.


Table 3 below shows various currents that were measured at 0.8V (nA) with various solutions. The voltage was applied in on-off pulse sequences in which the testing period concluded with the voltage being raised to 0.8V. The pulse sequences were the same for the testing of each of the solutions. Solutions 8-10 included non-ionic polymers-polyvinylpyrrolidone (PVP), 50 mV HEPES buffer, and polyvinyl alcohol (PVA), respectively. Solutions 11 and 12, on the other hand, included an anionic polymer-polyvinyl sulfonic acid (PVS) and polyacrylic acid (PAA), respectively. The voltage was applied in on-off pulse sequences in which the testing period concluded with the voltage being raised to 0.8V. Solutions 8-12 each included 10 mV of sodium diphenylamine-4-sulfonate (SDPAS).












TABLE 3








Current @


Solution #
Control Solution
Polymer
0.8 V (nA)


















8
10 mM SDPAS
2.3 PVP 55K
7,312


9
10 mM SDPAS
50 mM HEPES buffer
9,603


10
10 mM SDPAS
6% PVA
10,552


11
10 mM SDPAS
17.6% PVS
21,500


12
10 mM SDPAS
18.7% PAA 3K
21,600









As shown in Table 3, Solutions 11 and 12 with an anionic polymer had much higher currents than Solutions 8-10, which did not include an anionic polymer. Compare 21,500 and 21,600 nA of Solutions 11 and 12 with 7,312, 9,603 and 10,552 nA of Solutions 8-10.


Table 4 below shows various currents that were measured at 0.6V (nA) with various solutions. The voltage was applied in on-off pulse sequences in which the testing period concluded with the voltage being raised to 0.6V. The pulse sequences were the same for the testing of each of the solutions. Solution 13 included a non-ionic polymer-polyvinylpyrrolidone (PVP). Solution 14, on the other hand, included an anionic polymer-polyacrylic acid (PAA). The voltage was applied in on-off pulse sequences in which the testing period concluded with the voltage being raised to 0.6V. Solutions 13 and 14 each included 50 mV of HEPES.












TABLE 4








Current @


Solution #
Control Solution
Polymer
0.6 V (nA)


















13
15 mM TOOS
16% PVP 2.4K
9,480


14
15 mM TOOS
18.7% PAA 2K
20,788









As shown in Table 4, Solution 14 with an anionic polymer had a much higher current than Solution 13, which did not include an anionic polymer. Compare 20.788 nA of Solution 14 with 9,480 nA of Solution 13. Thus, anionic polymers, including PAA, increase the control marker current not because of its high polymer concentration, but rather because of the nature of its polymeric charge.


Example 14

Referring to FIG. 17, the current (in nA) was plotted against a control solution including several concentrations on sodium chloride (NaCl). The tested control solution included 50 mV of 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid sodium salt (TOOS), 2.3% of polyvinylpyrrolidone and a buffer of 50 mV HEPES at a pH of 7. The current was taken at 5.3 seconds in an on-off pulse sequence with the voltage being 0.6V. Specifically, there were six different solutions of NaCl that were tested −0M, 0.1M, 0.3 M, 0.5 M, 0.7 M and 1 M. As shown in FIG. 17, the measured current increased significantly as the amount of sodium chloride was increased in the control solution.


Example 15

Referring to FIGS. 18A, 18B, using the same data, control solution and blood samples with different glucose concentrations were plotted. Specifically, the control solution included 8-anilino-1-napthalenesulfonic acid and the polymer polyvinyl sulfonic acid (PVS). The control solutions also included three different concentrations of glucose. The blood samples had 40% hematocrit with glucose concentrations that varied between 20 and 1,200 mg/dL.


In FIG. 18A, the differential indexes (DI) of the control solutions and the blood samples were plotted against the glucose (in mg/dL). As shown in FIG. 18A, at very low glucose concentrations levels in the blood, it may be difficult to use only the differential index (DI) to differentiate between a control solution and a blood solution. Referring to FIG. 18B, the control solution, has current values (ihigh volt) well above 15,000 nA. Thus, if the current is less than a predetermined value (e.g., 12,000 nA), then a blood sample is being measured as shown in FIG. 18B. If the current is greater than 12,000 nA, then the DI is used as shown in FIG. 18A to determine if a control solution or a blood sample is being tested. At currents greater than 12,000 nA, the glucose concentrations of the blood samples are high (see FIG. 18A with the concentrations exceeding about 600 mg/dL). As shown in FIG. 18A, if the DI is greater than, for example, about 1.5 or 2.0, then the control solution is being tested. If the DI is less than about 1.5, then a blood sample is being tested since the DI values at high glucose concentrations are below this number.


Example 16


FIG. 19 shows the current plotted versus potential as the potential difference was cycled between −400 mV and +1,000 mV at 25 mV/sec using carbon electrodes. The testing was performed on an electrochemical work station of CH Instrument Co.


As shown in FIG. 19, Trace 1 represented the cyclic voltammogram of 50 mV MAOS N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline, sodium salt (MAOS) and the mediator (2′,5′-disulfophenylimino)-3H-phenothiazine. The sensor was manufactured with deposition of the mediator, enzyme, polymer and other ingredients. The large redox waves near 0 mV indicated the oxidation and reduction of the mediator in the sensor. The oxidation potential of the chemical species (MAOS) was about 400 to 700 mV higher than the mediator as shown in FIG. 19 by Trace 1. Thus, a low voltage at a potential of about 200 mV for the mediator and a high voltage at a potential in the range of about 400 to 700 mV for the control marker (MAOS) may be applied such that there is no overlap between the mediator's oxidation and the control marker's oxidation.


While the present invention has been described with reference to one or more particular embodiments, those skilled in the art will recognize that many changes may be made thereto without departing from the spirit and scope of the present invention. Each of these embodiments, and obvious variations thereof, is contemplated as falling within the spirit and scope of the invention.

Claims
  • 1. A method of using an electrochemical test sensor, the method comprising the acts of: introducing a fluid sample to the electrochemical test sensor;applying a pulse sequence to the fluid sample, the pulse sequence comprising at least two duty cycles within 180 seconds, at least one of the duty cycles having a first potential in a first excitation period and a first relaxation period, and after one of the duty cycles, providing a second potential to the sample, the second potential being greater than the first potential, the second potential being supplied after a second relaxation period, the second relaxation period being less than the first relaxation period;measuring a first current at the first potential responsive to an analyte;measuring a second current at the second potential responsive to the analyte; anddetermining whether the fluid sample is a control solution or an analyte-fluid test sample based on the measured first and second currents.
  • 2. The method of claim 1 wherein at least one of the first and second relaxation periods uses an open circuit.
  • 3. The method of claim 2 wherein the first and second relaxation periods use an open circuit.
  • 4. The method of claim 1 wherein each of the duty cycles uses the first potential.
  • 5. The method of claim 1 wherein the at least two duty cycles are from 3 to 18 duty cycles.
  • 6. The method of claim 5 wherein the at least two duty cycles are from 3 to 10 duty cycles.
  • 7. The method of claim 6 wherein the at least two duty cycles are performed in 30 seconds or less.
  • 8. The method of claim 1 wherein the at least two duty cycles are 3 to 8 duty cycles and are performed in 3 to 16 seconds.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 14/105,839 filed Dec. 13, 2013; U.S. application Ser. No. 14/105,839 is a continuation of U.S. application Ser. No. 13/682,380 filed Nov. 20, 2012; U.S. application Ser. No. 13/682,380 is a divisional of U.S. application Ser. No. 12/316,133 filed Dec. 10, 2008, which issued as U.S. Pat. No. 8,337,691 B2 on Dec. 25, 2012, all of which claim priority to U.S. Provisional Application No. 61/007,211, filed Dec. 10, 2007, the contents of which are incorporated entirely herein by reference.

US Referenced Citations (658)
Number Name Date Kind
3167651 Huett et al. Jan 1965 A
3420205 Morrison Jan 1969 A
3505136 Attwood Apr 1970 A
3510268 Hach May 1970 A
3551295 Dyer Dec 1970 A
3562041 Robertson Feb 1971 A
3573139 Mori et al. Mar 1971 A
3621381 Eckfeldt Nov 1971 A
3715192 Wenz et al. Feb 1973 A
3720093 Gill Mar 1973 A
3763422 MacPhee et al. Oct 1973 A
3770607 Williams Nov 1973 A
3776832 Oswin et al. Dec 1973 A
3791933 Wenz et al. Feb 1974 A
3791988 Bauer et al. Feb 1974 A
3806718 Stewart Apr 1974 A
3838033 Mindt et al. Sep 1974 A
3902970 Levin Sep 1975 A
3917453 Milligan et al. Nov 1975 A
3919627 Allen Nov 1975 A
3920580 Mast Nov 1975 A
3925183 Oswin et al. Dec 1975 A
3937615 Clack et al. Feb 1976 A
3948745 Guillbault et al. Apr 1976 A
3952183 Abe Apr 1976 A
3980437 Kishimoto et al. Sep 1976 A
4005002 Racine et al. Jan 1977 A
4008448 Muggli Feb 1977 A
4040908 Clark, Jr. Aug 1977 A
4053381 Hamblen et al. Oct 1977 A
4065263 Woodbridge et al. Dec 1977 A
4077861 Lauer Mar 1978 A
4123701 Josefsen et al. Oct 1978 A
4127448 Schick et al. Nov 1978 A
4137495 Brown Jan 1979 A
4184936 Paul et al. Jan 1980 A
4214968 Battaglia et al. Jul 1980 A
4217196 Huch Aug 1980 A
4224125 Nakamura et al. Sep 1980 A
4225410 Pace et al. Sep 1980 A
4229426 Haagensen, Jr. Oct 1980 A
4230537 Delente et al. Oct 1980 A
4233029 Columbus Nov 1980 A
4260680 Muramatsu et al. Apr 1981 A
4263343 Kim Apr 1981 A
4265250 Parker May 1981 A
4273639 Gottermeier May 1981 A
4297184 Dyer Oct 1981 A
4297569 Flies Oct 1981 A
4301412 Hill et al. Nov 1981 A
4303887 Hill et al. Dec 1981 A
4304853 Jozefonvicz et al. Dec 1981 A
4323536 Columbus Apr 1982 A
4329642 Luthi et al. May 1982 A
4366033 Richter et al. Dec 1982 A
4376689 Nakamura et al. Mar 1983 A
4381775 Nose et al. May 1983 A
4396464 Giner et al. Aug 1983 A
4402940 Nose et al. Sep 1983 A
4403984 Ash et al. Sep 1983 A
4407290 Wiber Oct 1983 A
4407959 Tsuji et al. Oct 1983 A
4413407 Columbus Nov 1983 A
4420564 Tsuji et al. Dec 1983 A
4431004 Bessman et al. Feb 1984 A
4436094 Cerami Mar 1984 A
4440175 Wilkins Apr 1984 A
4473457 Columbus Sep 1984 A
4476149 Poppe et al. Oct 1984 A
4477314 Richter et al. Oct 1984 A
4490216 McConnell Dec 1984 A
4499423 Matthiessen Feb 1985 A
4502938 Covington et al. Mar 1985 A
4517291 Seago May 1985 A
4545382 Higgins et al. Oct 1985 A
4547735 Kiesewetter et al. Oct 1985 A
4552458 Lowne Nov 1985 A
4561944 Sasaki et al. Dec 1985 A
4571292 Liu et al. Feb 1986 A
4572899 Walker et al. Feb 1986 A
4578716 Van Rijckevorsel et al. Mar 1986 A
4579893 Wang et al. Apr 1986 A
4582684 Vogel et al. Apr 1986 A
4592893 Wang et al. Apr 1986 A
4591550 Hafeman et al. May 1986 A
4628193 Blum Dec 1986 A
4642295 Baker Feb 1987 A
4648665 Davis et al. Mar 1987 A
4652830 Brown Mar 1987 A
4654197 Lilja et al. Mar 1987 A
4671288 Gough May 1987 A
4676653 Strohmeier et al. May 1987 A
4679532 Luksha Jul 1987 A
4680268 Clark, Jr. Jul 1987 A
4682602 Prohaska Jul 1987 A
4686479 Young et al. Aug 1987 A
4703017 Campbell et al. Oct 1987 A
4703756 Gough et al. Nov 1987 A
4713347 Mitchell et al. Dec 1987 A
4714874 Morris et al. Dec 1987 A
4721677 Clark, Jr. Jan 1988 A
4729959 Ryan Mar 1988 A
4731726 Allen et al. Mar 1988 A
4734184 Burleigh et al. Mar 1988 A
4745076 Muller et al. May 1988 A
4746607 Mura et al. May 1988 A
4750496 Reinhart et al. Jun 1988 A
4759828 Young et al. Jul 1988 A
4775575 Tang Oct 1988 A
4795542 Ross et al. Jan 1989 A
4797256 Watlington, IV Jan 1989 A
4805624 Yao et al. Feb 1989 A
4806311 Greenquist Feb 1989 A
4806312 Greenquist Feb 1989 A
4810203 Komatsu Mar 1989 A
4816224 Vogel et al. Mar 1989 A
4820399 Senda et al. Apr 1989 A
4820636 Hill et al. Apr 1989 A
4830595 McNeil et al. May 1989 A
4832814 Root May 1989 A
4834234 Sacherer et al. May 1989 A
4849330 Humphries et al. Jul 1989 A
4854153 Miyagawa et al. Aug 1989 A
4865873 Cole, Jr. et al. Sep 1989 A
4877580 Aronowitz et al. Oct 1989 A
4890926 Dosmann et al. Jan 1990 A
4894137 Takizawa et al. Jan 1990 A
4897162 Lewandoski et al. Jan 1990 A
4919770 Preidel et al. Apr 1990 A
4927516 Yamaqucji et al. May 1990 A
4929330 Osaka et al. May 1990 A
4929545 Freitage May 1990 A
4935105 Churchouse Jun 1990 A
4935106 Beach, Jr. et al. Jun 1990 A
4935346 Kugler Jun 1990 A
4938860 Wogoman Jul 1990 A
4940945 Littlejohn et al. Jul 1990 A
4954087 Lauks et al. Sep 1990 A
4956275 Zuk et al. Sep 1990 A
4963814 Parks et al. Oct 1990 A
4970145 Bennetto et al. Nov 1990 A
4975647 Downer et al. Dec 1990 A
4976724 Nieto Dec 1990 A
4999582 Parks et al. Mar 1991 A
4999632 Parks Mar 1991 A
5018164 Brewer et al. May 1991 A
5019974 Beckers May 1991 A
5028542 Kennamer et al. Jul 1991 A
5035862 Dietze et al. Jul 1991 A
5039618 Stone Aug 1991 A
5046618 Wood Sep 1991 A
5049487 Phillips et al. Sep 1991 A
5057477 Paterson et al. Oct 1991 A
5059199 Okada et al. Oct 1991 A
5059394 Phillips et al. Oct 1991 A
5066372 Weetall Nov 1991 A
5075077 Durley, III et al. Dec 1991 A
5096669 Lauks et al. Mar 1992 A
5096671 Kane et al. Mar 1992 A
5108819 Heller et al. Apr 1992 A
5112455 Cozzette et al. May 1992 A
5112758 Fellman et al. May 1992 A
5120421 Glass et al. May 1992 A
5118183 Cargill et al. Jun 1992 A
5120420 Nankai et al. Jun 1992 A
5122244 Hoenes et al. Jun 1992 A
5140176 Okino Aug 1992 A
5141850 Cole et al. Aug 1992 A
5141868 Shanks et al. Aug 1992 A
5143694 Schafer et al. Sep 1992 A
5155628 Dosmann Oct 1992 A
5179005 Phillips et al. Jan 1993 A
5179288 Miffitt et al. Jan 1993 A
5182707 Cooper et al. Jan 1993 A
5187100 Matzinger et al. Feb 1993 A
5192415 Yosioka et al. Mar 1993 A
5202261 Musho et al. Apr 1993 A
5217594 Henkens et al. May 1993 A
5220920 Gharib Jun 1993 A
5223117 Wrighton et al. Jun 1993 A
5229282 Yoshioka et al. Jul 1993 A
5232516 Hed Aug 1993 A
5232667 Hieb et al. Aug 1993 A
5232668 Grante et al. Aug 1993 A
5234813 MeGreenhan et al. Aug 1993 A
5243516 White Sep 1993 A
5246858 Arbuckle et al. Sep 1993 A
5250439 Mucho et al. Oct 1993 A
5261411 Hughes et al. Nov 1993 A
5264103 Yoshioka et al. Nov 1993 A
5266179 Nanki et al. Nov 1993 A
5269891 Colin Dec 1993 A
5279294 Anderson et al. Jan 1994 A
5281395 Markart et al. Jan 1994 A
5282950 Dietze et al. Feb 1994 A
5284770 Adrain et al. Feb 1994 A
5286362 Hoenes et al. Feb 1994 A
5304468 Phillips et al. Apr 1994 A
5306623 Kiser et al. Apr 1994 A
5311426 Donohue et al. May 1994 A
5312590 Gunasingham May 1994 A
5320732 Nankai et al. Jun 1994 A
5321492 Detwiler et al. Jun 1994 A
5332479 Uenoyama et al. Jul 1994 A
5334296 Henkens et al. Aug 1994 A
5344754 Zewing Sep 1994 A
5352351 White et al. Oct 1994 A
5353351 Bartoli et al. Oct 1994 A
5354447 Uenoyama et al. Oct 1994 A
5361314 Kopelman et al. Nov 1994 A
5366609 White et al. Nov 1994 A
5368707 Henkens et al. Nov 1994 A
5371687 Holmes, II et al. Dec 1994 A
5376254 Fisher Dec 1994 A
5379214 Arbuckle et al. Jan 1995 A
5384028 Ito Jan 1995 A
5389215 Horiuchi et al. Feb 1995 A
5391272 O'Daly et al. Feb 1995 A
5393903 Gratzel et al. Feb 1995 A
5395504 Saurer et al. Mar 1995 A
5403462 Lev et al. Apr 1995 A
5405511 White et al. Apr 1995 A
5410059 Fraser et al. Apr 1995 A
5410474 Fox Apr 1995 A
5411647 Johnson et al. May 1995 A
5413690 Kost et al. May 1995 A
5413764 Haar May 1995 A
5418142 Kiser et al. May 1995 A
5421189 Dussault May 1995 A
5424035 Hones et al. May 1995 A
5426032 Phillips et al. May 1995 A
5427912 Brown et al. May 1995 A
5429735 Johnson et al. Jul 1995 A
5437772 DeCastro et al. Aug 1995 A
5437999 Diebold et al. Aug 1995 A
5438271 White et al. Aug 1995 A
5439826 Kontorovich Aug 1995 A
5445967 Deuter Aug 1995 A
5447837 Urnovitz Sep 1995 A
5449898 Dosmann Sep 1995 A
5453360 Yu Sep 1995 A
5468366 Wegner et al. Nov 1995 A
5469846 Khan Nov 1995 A
5470533 Shindo et al. Nov 1995 A
5477326 Dosmann Dec 1995 A
5489414 Schreiber et al. Feb 1996 A
5494638 Gullick Feb 1996 A
5500350 Baker et al. Mar 1996 A
5502396 Desarzens et al. Mar 1996 A
5504011 Gavin et al. Apr 1996 A
5508171 Walling et al. Apr 1996 A
5508200 Tiffany et al. Apr 1996 A
5508203 Fuller et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5512159 Yoshioka et al. Apr 1996 A
5515847 Braig et al. May 1996 A
5518689 Dosmann et al. May 1996 A
5520786 Bloczynski et al. May 1996 A
5526111 Collins et al. May 1996 A
5526120 Jina et al. Jun 1996 A
5526808 Kaminsky et al. Jun 1996 A
5532128 Eggers et al. Jul 1996 A
5556789 Goerlach et al. Aug 1996 A
5552116 Yokota et al. Sep 1996 A
5554531 Zweig Sep 1996 A
5556042 Phillips et al. Oct 1996 A
5563031 Yu Oct 1996 A
5569591 Kell et al. Oct 1996 A
5569608 Sommer Oct 1996 A
5572159 McFarland Nov 1996 A
5575403 Charlton et al. Nov 1996 A
5575895 Ikeda et al. Nov 1996 A
5576073 Kickelhain Nov 1996 A
5580794 Allen Dec 1996 A
5589045 Hyodo Dec 1996 A
5589326 Deng et al. Dec 1996 A
5593390 Castellano et al. Jan 1997 A
5593739 Kickelhain Jan 1997 A
5594906 Holmes, II et al. Jan 1997 A
5597532 Connolly Jan 1997 A
5603820 Malinski et al. Feb 1997 A
5604110 Baker et al. Feb 1997 A
5605662 Heller et al. Feb 1997 A
5605837 Karimi et al. Feb 1997 A
5611909 Studer Mar 1997 A
5611999 Dosmann et al. Mar 1997 A
5620579 Genshaw et al. Apr 1997 A
5620863 Tomasco et al. Apr 1997 A
5620890 Kamps-Holtzapple et al. Apr 1997 A
5627922 Kopelman et al. May 1997 A
5628890 Carter et al. May 1997 A
5630986 Charlton et al. May 1997 A
5635362 Levine et al. Jun 1997 A
5635364 Clark et al. Jun 1997 A
5637505 Li et al. Jun 1997 A
5639671 Bogart et al. Jun 1997 A
5642734 Ruben et al. Jul 1997 A
5644501 Lin et al. Jul 1997 A
5645798 Schreiber et al. Jul 1997 A
5650061 Kuhr et al. Jul 1997 A
5650062 Ikeda et al. Jul 1997 A
5653863 Genshaw et al. Aug 1997 A
5654178 Fitzpatrick et al. Aug 1997 A
5656502 Mackay et al. Aug 1997 A
5658443 Yamamoto et al. Aug 1997 A
5658802 Hayes et al. Aug 1997 A
5660791 Brenneman et al. Aug 1997 A
5665215 Bussmann et al. Sep 1997 A
5670031 Hintsche et al. Sep 1997 A
5686659 Neel et al. Nov 1997 A
5691486 Behringer et al. Nov 1997 A
5691633 Liu et al. Nov 1997 A
5695623 Michel et al. Dec 1997 A
5698083 Glass Dec 1997 A
5700695 Yassinzadeh et al. Dec 1997 A
5701181 Boiarski et al. Dec 1997 A
5704354 Preidel et al. Jan 1998 A
5708247 McAleer et al. Jan 1998 A
5710011 Forrow et al. Jan 1998 A
5710622 Neel et al. Jan 1998 A
5719667 Miers Feb 1998 A
5720862 Hamamoto et al. Feb 1998 A
5723284 Ye Mar 1998 A
5723345 Yamauchi et al. Mar 1998 A
5727548 Hill et al. Mar 1998 A
5728074 Castellano et al. Mar 1998 A
5745308 Spangenberg et al. Apr 1998 A
5748002 Scott et al. May 1998 A
5757666 Schreiber et al. May 1998 A
5775953 Henning et al. May 1998 A
5759364 Charlton et al. Jun 1998 A
5759794 Levine et al. Jun 1998 A
5776710 Levine et al. Jul 1998 A
5780304 Matzinger et al. Jul 1998 A
5786584 Button et al. Jul 1998 A
5788833 Lewis et al. Aug 1998 A
5789255 Yu Aug 1998 A
5792668 Fuller et al. Aug 1998 A
5798031 Charlton et al. Aug 1998 A
5801057 Smart et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5820662 Kubo et al. Oct 1998 A
5832921 Lennert et al. Nov 1998 A
5834217 Levine et al. Nov 1998 A
5837546 Allen et al. Nov 1998 A
5843691 Douglas et al. Dec 1998 A
5843692 Phillips et al. Dec 1998 A
5846794 Delobeau et al. Dec 1998 A
5849174 Sanghera et al. Dec 1998 A
5856195 Charlton et al. Jan 1999 A
5856251 Park et al. Jan 1999 A
5863400 Drummond et al. Jan 1999 A
5873990 Wojciechowski et al. Feb 1999 A
5874046 Megerle et al. Feb 1999 A
5883378 Irish et al. Mar 1999 A
5885839 Lingane et al. Mar 1999 A
5890489 Elden Apr 1999 A
5904898 Market May 1999 A
5911872 Lewis et al. May 1999 A
5916156 Hildenbrand et al. May 1999 A
5921925 Cartmell et al. Jul 1999 A
5922530 Yu Jul 1999 A
5922591 Anderson et al. Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5942102 Hodges et al. Aug 1999 A
5945341 Howard, III Aug 1999 A
5948289 Noda et al. Sep 1999 A
5958199 Miyamto et al. Sep 1999 A
5965380 Heller et al. Oct 1999 A
5968760 Phillips et al. Oct 1999 A
5971923 Finger Oct 1999 A
5989917 McAleer et al. Nov 1999 A
6001239 Douglas et al. Dec 1999 A
6004441 Fujiwara et al. Dec 1999 A
6004442 Choulga et al. Dec 1999 A
6013170 Meade Jan 2000 A
6042714 Lin et al. Mar 2000 A
6044285 Chaiken et al. Mar 2000 A
6045567 Taylor et al. Apr 2000 A
6054039 Shieh Apr 2000 A
6061128 Zweig et al. May 2000 A
6069011 Riedel May 2000 A
6071391 Gotoh et al. Jun 2000 A
6087182 Jeng et al. Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6102872 Doneen et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6103509 Sode Aug 2000 A
6110354 Saban et al. Aug 2000 A
6103009 Heller et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121050 Han Sep 2000 A
6124461 Say et al. Oct 2000 A
6126609 Keith et al. Oct 2000 A
6128519 Say Oct 2000 A
6129823 Hughes et al. Oct 2000 A
6136549 Feistel Oct 2000 A
6136610 Polito et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6143247 Sheppard, Jr. et al. Nov 2000 A
6144869 Berner et al. Nov 2000 A
6150124 Riedel Nov 2000 A
6156051 Schraga Dec 2000 A
6156173 Gotoh et al. Dec 2000 A
6156673 Hintermaier et al. Dec 2000 A
6157442 Raskas Dec 2000 A
6157472 Eum et al. Dec 2000 A
6159745 Roberts et al. Dec 2000 A
6162611 Heller et al. Dec 2000 A
6162639 Douglas Dec 2000 A
6168563 Brown Jan 2001 B1
6168957 Matzinger et al. Jan 2001 B1
6170318 Lewis Jan 2001 B1
6174420 Hodges et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6176988 Kessler Jan 2001 B1
6179979 Hodges et al. Jan 2001 B1
6180062 Naka et al. Jan 2001 B1
6181417 Dosmann Jan 2001 B1
6193873 Oharra et al. Feb 2001 B1
6197040 LeVaughn et al. Mar 2001 B1
6200773 Ouyang et al. Mar 2001 B1
6201607 Roth et al. Mar 2001 B1
6203952 O'Brian et al. Mar 2001 B1
6206282 Hayes, Sr. et al. Mar 2001 B1
6206292 Roberts et al. Mar 2001 B1
6207000 Schwobel et al. Mar 2001 B1
6212417 Ikeda et al. Apr 2001 B1
6218571 Zhena et al. Apr 2001 B1
6225078 Ikeda et al. May 2001 B1
6226081 Fantone et al. May 2001 B1
6233471 Berner et al. May 2001 B1
6241862 McAlleer et al. May 2001 B1
6246862 Perry et al. May 2001 B1
6246966 Perry May 2001 B1
6251260 Heller et al. Jun 2001 B1
6259937 Schulman et al. Jul 2001 B1
6261519 Harding et al. Jul 2001 B1
6262749 Finger et al. Jul 2001 B1
6268162 Phillips et al. Jul 2001 B1
6270637 Crismore et al. Aug 2001 B1
6271044 Ballerstadt et al. Aug 2001 B1
6272262 Kopelman et al. Aug 2001 B1
6272364 Kurnok Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6277641 Yager Aug 2001 B1
6281006 Heller et al. Aug 2001 B1
6284550 Carroll et al. Sep 2001 B1
6287595 Loewy et al. Sep 2001 B1
6294281 Heller Sep 2001 B1
6294787 Schieferdecker et al. Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6299757 Feldman et al. Oct 2001 B1
6300142 Vadgama et al. Oct 2001 B1
6300961 Finger et al. Oct 2001 B1
6309526 Fujiwara et al. Oct 2001 B1
6315951 Markart Nov 2001 B1
6316264 Corey et al. Nov 2001 B1
6326160 Dunn et al. Dec 2001 B1
6329161 Heller et al. Dec 2001 B1
6330464 Colvin, Jr. et al. Dec 2001 B1
6335203 Patel et al. Jan 2002 B1
6338790 Feldman et al. Jan 2002 B1
6340428 Ikeada et al. Jan 2002 B1
6342364 Watanabe et al. Jan 2002 B1
6344133 Formica et al. Feb 2002 B1
6349230 Kawanaka et al. Feb 2002 B1
6358752 Durst et al. Mar 2002 B1
6377896 Sato et al. Apr 2002 B1
6379513 Chambers et al. Apr 2002 B1
6379915 Douglas et al. Apr 2002 B1
6339258 O'Brien et al. May 2002 B1
6389891 D'Angelico et al. May 2002 B1
6391558 Henkens et al. May 2002 B1
6391645 Huang et al. May 2002 B1
6394952 Anderson et al. May 2002 B1
6395227 Kiser et al. May 2002 B1
6401532 Lubbers Jun 2002 B2
6413398 Geoff et al. Jul 2002 B1
6414213 Ohmori et al. Jul 2002 B2
6414395 Ookuma et al. Jul 2002 B1
6414410 Nakamura et al. Jul 2002 B1
6420128 Ouyang et al. Jul 2002 B1
6444115 Hodges et al. Sep 2002 B1
6447657 Bhullar et al. Sep 2002 B1
6454921 Hodges et al. Sep 2002 B1
6461496 Feldman et al. Oct 2002 B1
6475372 Ohara et al. Nov 2002 B1
6485923 Yani et al. Nov 2002 B1
6488827 Shartle Dec 2002 B1
6489133 Phillips et al. Dec 2002 B2
6491803 Shen et al. Dec 2002 B1
6491870 Patel et al. Dec 2002 B2
6501976 Sohrab Dec 2002 B1
6503381 Gotoh et al. Jan 2003 B1
6512986 Harmon Jan 2003 B1
6514718 Heller et al. Feb 2003 B2
6521110 Hodges et al. Feb 2003 B1
6521182 Shade et al. Feb 2003 B1
6525330 Paolini et al. Feb 2003 B2
6525549 Poellmann Feb 2003 B1
6526298 Khalil et al. Feb 2003 B1
6531040 Musho et al. Mar 2003 B2
6531239 Heller Mar 2003 B2
6531322 Jurik et al. Mar 2003 B1
6535753 Raskas Mar 2003 B1
6537498 Lewis et al. Mar 2003 B1
6538735 Duebendorfer et al. Mar 2003 B1
6540890 Bhullar et al. Apr 2003 B1
6540891 Stewart et al. Apr 2003 B1
6541266 Modzelewski et al. Apr 2003 B2
6544474 Douglas et al. Apr 2003 B2
6549796 Sohrab Apr 2003 B2
6551494 Heller et al. Apr 2003 B1
6555061 Leong et al. Apr 2003 B1
6558528 Matzinger May 2003 B1
6558529 McVey et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6562625 Modzelewski et al. May 2003 B2
6565509 Say et al. May 2003 B1
6570390 Hirayama et al. May 2003 B2
6571651 Hodges May 2003 B1
6572822 Jurki et al. May 2003 B2
6574425 Weiss et al. May 2003 B1
6576416 Haviland et al. May 2003 B2
6576461 Heller et al. May 2003 B2
6579690 Bonnecaze May 2003 B1
6576101 Heller et al. Jun 2003 B1
6591125 Buse et al. Jul 2003 B1
6592744 Hodges et al. Jul 2003 B1
6592745 Feldmen et al. Jul 2003 B1
6594514 Berner et al. Jul 2003 B2
6600997 Deweese et al. Jul 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607658 Heller et al. Aug 2003 B1
6618934 Feldmen et al. Sep 2003 B1
6623501 Heller et al. Sep 2003 B2
6627057 Bullar et al. Sep 2003 B1
6632349 Hodges et al. Oct 2003 B1
6636652 Kopelman et al. Oct 2003 B1
6638415 Hodges et al. Oct 2003 B1
6638716 Heller et al. Oct 2003 B2
6645359 Bhullar et al. Nov 2003 B1
6645368 Beaty et al. Nov 2003 B1
6654625 Say et al. Nov 2003 B1
6656702 Yugawa et al. Dec 2003 B1
6656741 Nelson et al. Dec 2003 B1
6676816 Mao et al. Jan 2004 B2
6676995 Dick et al. Jan 2004 B2
6689265 Heller et al. Feb 2004 B2
6689411 Dick et al. Feb 2004 B2
6690836 Natarajan et al. Feb 2004 B2
6699384 Lin et al. Mar 2004 B1
6749740 Liamos et al. Jun 2004 B2
6790341 Saba et al. Sep 2004 B1
6824670 Tokunaga et al. Nov 2004 B2
6841052 Musho et al. Jan 2005 B2
6890421 Oharra et al. May 2005 B2
6893545 Gotoh et al. May 2005 B2
6942518 Liamos et al. Sep 2005 B2
7018843 Heller Mar 2006 B2
7122111 Tokunaga et al. Oct 2006 B2
7132041 Deng et al. Nov 2006 B2
7176146 Wilsey Oct 2007 B2
7351323 Iketaki et al. Apr 2008 B2
8002965 Beer et al. Aug 2011 B2
8026104 Wu et al. Sep 2011 B2
8088272 Deng Jan 2012 B2
8101062 Deng Jan 2012 B2
8147674 Wu Apr 2012 B2
8234076 Carpenter et al. Jul 2012 B2
8262899 Wu Sep 2012 B2
8287717 Wu Oct 2012 B2
8337691 Lin et al. Dec 2012 B2
8404100 Wu Mar 2013 B2
8425757 Wu et al. Apr 2013 B2
8470604 Wu et al. Jun 2013 B2
8716024 Lin et al. May 2014 B2
8871517 Lin et al. Oct 2014 B2
20010000129 Raskas Apr 2001 A1
20010017269 Heller et al. Aug 2001 A1
20010042683 Musho et al. Nov 2001 A1
20020004106 Leddy et al. Jan 2002 A1
20020012821 Leddy et al. Jan 2002 A1
20020053523 Liamos et al. May 2002 A1
20020079219 Zhao et al. Jun 2002 A1
20020081588 De Lumley-Woodyear et al. Jun 2002 A1
20020084196 Liamos et al. Jul 2002 A1
20020125146 Chan et al. Sep 2002 A1
20020139692 Tokunaga et al. Oct 2002 A1
20020157967 Ling et al. Oct 2002 A1
20020180446 Kuhr et al. Dec 2002 A1
20030064525 Liess Apr 2003 A1
20030148169 Willmer et al. Apr 2003 A1
20030113933 Rasmus et al. Jun 2003 A1
20030119208 Yoon et al. Jun 2003 A1
20030136673 Pilloud et al. Jul 2003 A1
20030146110 Karinka et al. Aug 2003 A1
20030149348 Raskas Aug 2003 A1
20030159927 Lewis et al. Aug 2003 A1
20030175737 Schulien et al. Sep 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030178322 Bolon et al. Sep 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030201194 Heller et al. Oct 2003 A1
20030205465 Feng et al. Nov 2003 A1
20030209450 McVey et al. Nov 2003 A1
20040005716 Beaty et al. Jan 2004 A9
20040007461 Edelbrock Jan 2004 A1
20040026253 Leddy et al. Feb 2004 A1
20040029946 Arora et al. Feb 2004 A1
20040033165 Lewis et al. Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045821 Cui et al. Mar 2004 A1
20040054267 Feldmen et al. Mar 2004 A1
20040055898 Heller et al. Mar 2004 A1
20040060818 Feldmen et al. Apr 2004 A1
20040061841 Black et al. Apr 2004 A1
20040074472 Kumar et al. Apr 2004 A1
20040079653 Karinka et al. Apr 2004 A1
20040099531 Srinivasan et al. May 2004 A1
20040118682 Murray et al. Jun 2004 A1
20040149577 Kumar et al. Aug 2004 A1
20040157337 Burke et al. Aug 2004 A1
20040157338 Burke et al. Aug 2004 A1
20040157339 Burke et al. Aug 2004 A1
20040180444 Rannikko et al. Sep 2004 A1
20040224137 Rogalska et al. Nov 2004 A1
20040225230 Liamos et al. Nov 2004 A1
20040256248 Burke et al. Dec 2004 A1
20040259180 Burke et al. Dec 2004 A1
20040260511 Burke et al. Dec 2004 A1
20050009126 Andrews et al. Jan 2005 A1
20050049473 Desai et al. Mar 2005 A1
20050069892 Lyengar et al. Mar 2005 A1
20050164322 Heller et al. Jul 2005 A1
20050176153 O'hara et al. Aug 2005 A1
20050247562 Tokunaga et al. Nov 2005 A1
20060063218 Bartkowiak et al. Mar 2006 A1
20060074564 Bartkowiak et al. Apr 2006 A1
20060085137 Bartkowiak et al. Apr 2006 A1
20060191787 Wang et al. Aug 2006 A1
20070074977 Guo et al. Apr 2007 A1
20070080073 Wu et al. Apr 2007 A1
20070256943 Popovich et al. Nov 2007 A1
20080102441 Chen et al. May 2008 A1
20080145878 Marfurt Jun 2008 A1
20080149480 Bell Jun 2008 A1
20080311613 Stefaniak et al. Dec 2008 A1
20090014339 Beer et al. Jan 2009 A1
20090026094 Deng et al. Jan 2009 A1
20090084687 Chatelier Apr 2009 A1
20090305317 Brauer et al. Dec 2009 A1
20120211361 Wu Aug 2012 A1
20120298507 Wu Nov 2012 A1
20130240377 Wu Sep 2013 A1
20140174951 Beer et al. Jun 2014 A1
Foreign Referenced Citations (170)
Number Date Country
2423837 Oct 2000 CA
2358993 May 2001 CA
1322299 Oct 2000 CN
1328156 Dec 2001 CN
1598564 Oct 2004 CN
229500 Jun 1985 DE
271179 Aug 1989 DE
4003194 Aug 1991 DE
4100727 Jul 1992 DE
19944318891 Dec 1994 DE
19824629 Dec 1999 DE
69915850 Jan 2005 DE
34049 Aug 1981 EP
57110 Aug 1982 EP
120715 Oct 1984 EP
121385 Oct 1984 EP
127958 Dec 1984 EP
10375 Dec 1985 EP
164180 Dec 1985 EP
255291 Feb 1986 EP
206218 Dec 1986 EP
213343 Mar 1987 EP
215678 Mar 1987 EP
230472 Aug 1987 EP
241309 Oct 1987 EP
287883 Oct 1988 EP
330517 Feb 1989 EP
354441 Feb 1990 EP
359531 Mar 1990 EP
359831 Mar 1990 EP
383322 Aug 1990 EP
417796 Mar 1991 EP
470649 Feb 1992 EP
471986 Feb 1992 EP
537761 Apr 1993 EP
546536 Jun 1993 EP
546796 Jun 1993 EP
0628810 Dec 1994 EP
636880 Feb 1995 EP
640832 Mar 1995 EP
651250 May 1995 EP
186286 Jul 1996 EP
732406 Sep 1996 EP
732590 Sep 1996 EP
0741186 Nov 1996 EP
0762112 Mar 1997 EP
800086 Oct 1997 EP
837320 Apr 1998 EP
840122 May 1998 EP
851224 Jul 1998 EP
859230 Aug 1998 EP
878708 Nov 1998 EP
878713 Nov 1998 EP
887421 Dec 1998 EP
894509 Feb 1999 EP
942278 Sep 1999 EP
964059 Dec 1999 EP
1156324 Nov 2002 EP
1279742 Jan 2003 EP
1411348 Apr 2004 EP
1 557 662 Jul 2005 EP
1 840 219 Oct 2007 EP
2184236 Jan 2003 ES
2223185 Feb 2005 ES
2325920 Sep 1976 FR
2295676 Jun 1996 GB
62209350 Sep 1987 JP
3260739 Nov 1991 JP
09089832 Apr 1997 JP
11087213 Mar 1999 JP
2120657 May 1999 JP
2003028826 Jan 2003 JP
200361650 Mar 2003 JP
200403478 Jan 2004 JP
2004093478 Mar 2004 JP
2004300328 Oct 2004 JP
2005147990 Jun 2005 JP
WO 1981001794 Jul 1981 WO
WO 1982003729 Oct 1982 WO
WO 1983000926 Mar 1983 WO
WO 1986000138 Jan 1986 WO
WO 1986002732 May 1986 WO
WO 1990005293 May 1990 WO
WO 1990005910 May 1990 WO
WO 1992001928 Feb 1992 WO
WO 1992007655 May 1992 WO
WO 1992015704 Sep 1992 WO
WO 1992015859 Sep 1992 WO
WO 1992015861 Sep 1992 WO
WO 1992015950 Sep 1992 WO
WO 1992019961 Nov 1992 WO
WO 1992022669 Dec 1992 WO
WO 1993009433 May 1993 WO
WO 199321928 Nov 1993 WO
WO 199503542 Feb 1995 WO
WO 1995007050 Mar 1995 WO
WO 199513535 May 1995 WO
WO 199513536 May 1995 WO
WO 1995022597 Aug 1995 WO
WO 1996004398 Feb 1996 WO
WO 1996007908 Mar 1996 WO
WO 1996013707 May 1996 WO
WO 1996015454 May 1996 WO
WO 1996014026 Oct 1996 WO
WO 1996033403 Oct 1996 WO
WO 1997000441 Jan 1997 WO
WO 1997002487 Jan 1997 WO
WO 1997008544 Mar 1997 WO
WO 1997016726 May 1997 WO
WO 1997018465 May 1997 WO
WO 1997029366 Aug 1997 WO
WO 1997029847 Aug 1997 WO
WO 1997030344 Aug 1997 WO
WO 1997039343 Oct 1997 WO
WO 1997042882 Nov 1997 WO
WO 1997042888 Nov 1997 WO
WO 1997045719 Dec 1997 WO
WO 1998005424 Feb 1998 WO
WO 1998019153 May 1998 WO
WO 1998019159 May 1998 WO
WO 1998029740 Jul 1998 WO
WO 1998044342 Oct 1998 WO
WO 1998058246 Dec 1998 WO
WO 1998058250 Dec 1998 WO
WO 1999022227 May 1999 WO
WO 199922230 May 1999 WO
WO 1999045375 Sep 1999 WO
WO 199967628 Dec 1999 WO
WO 2000016089 Mar 2000 WO
WO 2000020626 Apr 2000 WO
WO 2000020855 Apr 2000 WO
WO 2000029540 May 2000 WO
WO 2000057011 Sep 2000 WO
WO 2000077523 Dec 2000 WO
WO 2001003207 Jan 2001 WO
WO 2001033206 May 2001 WO
WO 200133216 May 2001 WO
WO 2001056771 Aug 2001 WO
WO 2001057510 Aug 2001 WO
WO 2001057513 Aug 2001 WO
WO 200165246 Sep 2001 WO
WO 200167099 Sep 2001 WO
WO 2002001214 Jan 2002 WO
WO 2002031482 Apr 2002 WO
WO 2002031481 Oct 2002 WO
WO 2002077633 Oct 2002 WO
WO 2003001195 Jan 2003 WO
WO 2003069304 Feb 2003 WO
WO 2003066554 Jun 2003 WO
WO 2003087802 Oct 2003 WO
WO 2004023128 Mar 2004 WO
WO 2004040286 May 2004 WO
WO 2004046707 Jun 2004 WO
WO 2004053476 Jun 2004 WO
WO 2004062801 Jul 2004 WO
WO 2004113896 Dec 2004 WO
WO 2004113912 Dec 2004 WO
WO 2004113913 Dec 2004 WO
WO 2005001462 Jan 2005 WO
WO 2005001463 Jan 2005 WO
WO 2005003622 Jan 2005 WO
WO 2005003748 Jan 2005 WO
WO 2005008231 Jan 2005 WO
WO 2005022143 Mar 2005 WO
WO 2005040407 May 2005 WO
WO 2005045234 May 2005 WO
WO 2005078118 Aug 2005 WO
WO 2006012940 Feb 2006 WO
WO 2006079797 Aug 2006 WO
WO 2006110504 Oct 2006 WO
Non-Patent Literature Citations (7)
Entry
Dalrymple-Alford, P., et al., “Peak Shapes in Semi-differential Electroanalysis”, “Anal. Chem.”, 1977, pp. 1390-1394, vol. 49, No. 9, Publisher: American Chemical Society , Published in: USA.
Hall, J.W. et al., “Automated Determination of Glucose using ENZ Glucose Oxidase and Potassium Ferrocyanide ENZ Peroxidase,” Analytical Biochemistry, vol. 26, No. 1, 1968, pp. 12-17.
Stanislawski et al., “Immunotoxins Containing Glucose Oxidase and Lactoperoxidase With Tumoricidal Properties: In-Vitro Killing Effectiveness in a Mouse Plasmacytoma Cell Model,” Cancer Research 49, pp. 5497-5504 (Oct. 15, 1989).
Yao, et al., “A Thin-Film Glucose Electrode System with Compensation for Drifit”, 1989, pp. 742-744, vol. XX XV.
Yao, et al., “The Low-Potential Approach of Glucose Sensing”, 1986, pp. 139-146, vol. BME-33, No. 2.
PCT Search Report for International Application No. PCT/US2008/085903 dated May 18, 2009 (6 pages).
PCT Written Opinion for International Application No. PCT/US2008/085903 dated May 18, 2009 (11 pages).
Related Publications (1)
Number Date Country
20150008143 A1 Jan 2015 US
Provisional Applications (1)
Number Date Country
61007211 Dec 2007 US
Divisions (2)
Number Date Country
Parent 14105839 Dec 2013 US
Child 14491272 US
Parent 12316133 Dec 2008 US
Child 13682380 US
Continuations (1)
Number Date Country
Parent 13682380 Nov 2012 US
Child 14105839 US